Kidney mass lesions are common and are often discovered accidentally. Renal cell carcinoma (RCC) represents approximately 5% of all cancers. Men have a two-fold higher likelihood of developing the disease and experience a higher mortality rate than females. The differences between the genders are attributed to individual variations, including hereditary factors, underlying medical conditions, genetics, lifestyle, hormonal factors, and others, such as hypertension and obesity. Renal tumors are usually asymptomatic; however, hematuria, dull aching flank pain, and lower abdomen pain can present symptoms. A tissue biopsy is typically unnecessary but may be required in certain cases. Men tend to exhibit larger and more severe tumors. Radiology tools application is helpful for early diagnosis and follow-up. Partial or radial nephrectomy is an effective curative therapy in localized renal masses. Nevertheless, immunotherapy, cryotherapy, and sometimes chemotherapy are used, especially in high-income nations. In this review, epidemiology, pathophysiology, risk factors, presentation, diagnosis, and kidney mass management will be reviewed and updated. Different keywords and phrases, such as kidney malignancy, renal cancer, epidemiology of kidney cancer, nephrectomy in kidney masses, and management of renal cell tumors, were used to search PubMed, EMBASE, Scopus, Google, and Google Scholar for new reviews and original articles and new comments with updates that were published between January 2019 and May 2025.
Breast cancer commonly metastasizes to the bones, liver, lungs, and brain. However, metastasis to endocrine glands, particularly the adrenal and pituitary glands, is rare. We report the case of a 54-year-old woman with hormone receptor–positive, HER2-negative invasive ductal carcinoma of the right breast who initially showed a favorable response to standard therapy. Surveillance imaging in late 2022 revealed a left adrenal mass, subsequently confirmed as metastatic breast carcinoma. Following laparoscopic adrenalectomy, she developed primary adrenal insufficiency. By mid-2023, she presented with pituitary metastases, resulting in hypopituitarism, diabetes insipidus, and severe visual impairment. Despite targeted radiosurgery, her disease progressed rapidly, and she died in December 2024. This case illustrates an unusual metastatic pattern involving both the adrenal and pituitary glands and demonstrates the potential for aggressive clinical behavior even in hormone receptor–positive breast cancer. Clinicians should maintain a high index of suspicion for atypical metastatic sites to ensure timely diagnosis and optimize palliative care strategies.
To the editor, Breast cancer remains one of the leading causes of cancer-related mortality worldwide, necessitating innovative and multifaceted therapeutic strategies. [1] We propose a promising combination approach that synergizes Artificial Intelligence (AI), oncolytic virotherapy, probiotic therapy, stem cell therapy, and immunotherapy to target breast cancer more effectively.